The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell Derived Therapies [Cell Biology]

December 20th, 2013 by Scheiner, Z., Talib, S., Feigal, E. G.

Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cellular therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune privileged. However, there are reasons to question this assumption, including recent studies that have tested iPSC immunogenicity in various ways with conflicting results. Understanding the risk of an immune response and developing strategies to minimize this risk will be important steps before clinical testing. Here, we review the evidence for autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.